Clinical trial · Observational
Development of a Prediction Platform for Neoadjuvant Treatment and Prognosis in Pancreatic Cancer Using Organoid
Development of a Prediction Platform for Neoadjuvant Treatment and Prognosis in Pancreatic Cancer Using Ex Vivo Analysis of Organoid Culture
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators create organoid from the pancreatic cancer tissue obtained via EUS-FNA and EUS-FNB within the pancreatic cancer diagnostic process. And also the investigators create organoid from the pancreatic cancer tissue obtained after surgery as part of the pancreatic cancer treatment process. Check for the reactivity to anti-cancer drugs through cell viability assay after treating with various anti-cancer drugs, such as anti-cancer drugs used as neoadjuvant chemotherapy for pancreatic cancer to the organoid. Also, perform genomic analysis on each organoid, and then check if there are any unique genomic mutations for each organoid. By recognizing the relationship between the unique genomic mutations and reactivity to the anti-cancer drug within pancreatic cancer patients eligible for surgery, the investigators aim to strategize appropriate neoadjuvant chemotherapy before surgery, thus developing a platform to predict the outcomes of each patient.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreas Cancer | Pancreatic Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Organoid | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with resectable pancreatic cancer after neoadjuvant chemotherapy
- interventionNames
- Other: Organoid
Primary outcomes (1)
- measure
- Overall survival rate
- timeFrame
- From date of initiation of adjuvant chemotherapy after surgery until the date of death from any cause, assessed up to 36 months
- description
- The percentage of people in a group who are still alive for a certain period of time after they were started adjuvant chemotherapy for pancreatic cancer
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. 18 years old or older 2. Newly discovered pancreatic cancer and not a relapse 3. Diagnosed with pancreatic cancer via EUS-FNA, EUS-FNB before surgery 4. who is in need of neoadjuvant chemotherapy before surgery 5. Patients who can undergo surgery for pancreatic cancer after neoadjuvant chemotherapy 6. Diagnosed with pancreatic cancer from the final tissue pathology diagnosis after surgery 7. Able to make decisions for oneself for participation 8. Has obtained voluntary consent in written form (if 70 years of age or older, receive consent from the guardian as well) Exclusion Criteria: • None
References
Publications (0)
Data not yet available